Innate Pharma S.A.. (1/4/17). "Press Release: Upcoming Investor Conferences". Marseille.

	Region	London, Greater London
	Country	United Kingdom (GB)
	Organisation	Innate Pharma S.A. (Euronext Paris: IPH, Nasdaq: IPHA)
	Organisation 2	Oddo & Cie.
	Group	Oddo (Group)
	Product	J.P. Morgan 35th Annual Healthcare Conference 2017 San Francisco
	Product 2	Leerink Partners Annual Global Healthcare Conference 2017 New York
	Index term	Innate Pharma–JPMorgan Chase: investor conference, 201701 supply service Innate Pharma SA presents at JP Morgan Healthcare Conference 2017
	Index term 2	Innate Pharma–Leerink: investor conference, 201702 supply service Innate Pharma presents at Leerink Global Healthcare Conference in New York
	Person	Mahjoubi, Mondher (Innate Pharma 201612– CEO before AstraZeneca + Genentech + Aventis + Sanofi)
	Person 2	Mercier, Laure-Hélène (Innate Pharma 201612 CFO– before EVP Finance before Head Investor Relations)

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that it will be present at four upcoming investor conferences in Q1 2017, where Innate Pharma’s management team, including Mondher Mahjoubi, the newly appointed Chief Executive Officer and Chairman of Innate Pharma’s Executive Board, will provide an overview of the Company.

The four investor conferences in Q1 2017 are:

- Oddo Midcap Forum – Lyon, France, January 5-6

- J.P. Morgan 35th Annual Healthcare Conference – San Francisco, CA, USA, January 9-12

- Leerink Partners 6th Annual Global Healthcare Conference – New York, NY, USA, February 15-16

- Credit Suisse London One on One Global Healthcare Conference – London, UK, February 28-March 1

Innate Pharma is committed to meet on a regular basis with the financial community. All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company’s website in the Investors’ section (http://www.innate-pharma.com/en/investors).

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biotechnology company with a focus on discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients.

Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells.

The Company’s aim is to become a commercial stage biopharmaceutical company in the area of immunotherapy and focused on serious unmet medical needs in cancer. Innate Pharma has pioneered the discovery and development of checkpoint inhibitors to activate the innate immune system. Innate Pharma's innovative approach has resulted in three first-in-class, clinical-stage antibodies targeting natural killer cell receptors that may address a broad range of solid and hematological cancer indications as well as additional preclinical product candidates and technologies. Targeting receptors involved in innate immunity also creates opportunities for the Company to develop therapies for inflammatory diseases.

The Company's expertise and understanding of natural killer cell biology have enabled it to enter into major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi.

Based in Marseille, France, Innate Pharma has more than 150 employees and is listed on Euronext Paris.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:
ISIN code
Ticker code
FR0010331421
IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma’s website.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Innate Pharma
Laure-Hélène Mercier
Chief Financial Officer
Tel.: +33 (0)4 30 30 30 87
investors@innate-pharma.com
International Media and Investor Relations

Consilium Strategic Communications
Mary-Jane Elliott / Sue Stuart /
Jessica Hodgson / Hendrik Thys
Tel.: +44 (0)20 3709 5700
InnatePharma@consilium-comms.com

ATCG Press (France)
Marie Puvieux
Mob: +33 (0)6 10 54 36 72
presse@atcg-partners.com

Record changed: 2023-06-05